WO2007079171A3 - Traitement du lymphome de hodgkin - Google Patents

Traitement du lymphome de hodgkin Download PDF

Info

Publication number
WO2007079171A3
WO2007079171A3 PCT/US2006/049468 US2006049468W WO2007079171A3 WO 2007079171 A3 WO2007079171 A3 WO 2007079171A3 US 2006049468 W US2006049468 W US 2006049468W WO 2007079171 A3 WO2007079171 A3 WO 2007079171A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoma
hodgkin
treatment
ameliorate
symptom
Prior art date
Application number
PCT/US2006/049468
Other languages
English (en)
Other versions
WO2007079171A2 (fr
Inventor
Jeffrey S Miller
Carla Yunis
Original Assignee
Coley Pharm Group Inc
Jeffrey S Miller
Carla Yunis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Group Inc, Jeffrey S Miller, Carla Yunis filed Critical Coley Pharm Group Inc
Publication of WO2007079171A2 publication Critical patent/WO2007079171A2/fr
Publication of WO2007079171A3 publication Critical patent/WO2007079171A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne une méthode de traitement du lymphome de Hodgkin. De façon générale, la méthode consiste à administrer à un patient atteint du lymphome de Hodgkin une quantité d'un composé agoniste des TLR efficace pour traiter au moins un symptôme ou signe clinique du lymphome de Hodgkin.
PCT/US2006/049468 2005-12-28 2006-12-28 Traitement du lymphome de hodgkin WO2007079171A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75447305P 2005-12-28 2005-12-28
US60/754,473 2005-12-28

Publications (2)

Publication Number Publication Date
WO2007079171A2 WO2007079171A2 (fr) 2007-07-12
WO2007079171A3 true WO2007079171A3 (fr) 2007-11-08

Family

ID=38228846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049468 WO2007079171A2 (fr) 2005-12-28 2006-12-28 Traitement du lymphome de hodgkin

Country Status (1)

Country Link
WO (1) WO2007079171A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045260A1 (es) 2003-08-12 2005-10-19 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos
MXPA06002199A (es) 2003-08-27 2006-05-22 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
WO2005023190A2 (fr) 2003-09-05 2005-03-17 3M Innovative Properties Company Traitement pour le lymphome a cellules b cd5+
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2545774A1 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitues par oxime
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
CA2547020C (fr) 2003-11-25 2014-03-25 3M Innovative Properties Company Derives de 1h-imidazo[4,5-c]pyridine-4-amine en tant que compose modificateur de la reponse immunitaire
WO2005066170A1 (fr) 2003-12-29 2005-07-21 3M Innovative Properties Company Imidazoquinolines a substitution arylalcenyle et arylalkynyle
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
WO2005094531A2 (fr) 2004-03-24 2005-10-13 3M Innovative Properties Company Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (fr) 2004-06-18 2006-06-22 3M Innovative Properties Company Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (fr) 2004-06-18 2006-04-13 3M Innovative Properties Company Imidazonaphthyridines substituees par aryle
WO2006074003A2 (fr) 2004-12-30 2006-07-13 3M Innovative Properties Company Composes chiraux a cycle [1,2]imidazo[4,5] fusionne
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2006086634A2 (fr) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Composes cycliques imidazo[4,5-c] substitues par oxime et hydroxylamine et procedes associes
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
RU2457874C1 (ru) * 2011-06-30 2012-08-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ И СОЦИАЛЬНОГО РАЗВИТИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГУ "РНЦРХТ" Минздравсоцразвития России) Способ лечения лимфомы ходжкина iia стадии

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8
US20050281813A1 (en) * 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20050281813A1 (en) * 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8

Also Published As

Publication number Publication date
WO2007079171A2 (fr) 2007-07-12

Similar Documents

Publication Publication Date Title
WO2007079171A3 (fr) Traitement du lymphome de hodgkin
WO2007079146A8 (fr) Traitement pour un lymphome non hodgkinien
WO2007079202A3 (fr) Traitement pour une leucémie lymphoblastique aiguë
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
WO2007079169A3 (fr) Traitement pour une leucémie myéloïde aiguë
WO2006113942A3 (fr) Procede d'inhibition de l'activite de cathepsine
WO2006078463A3 (fr) Methode de traitement de maladie cardio-vasculaire
PL381247A1 (pl) Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
WO2006053043A3 (fr) Methodes de traitement du diabete sucre
WO2003057698A3 (fr) Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
SI1984357T1 (sl) Spojine 2,4-pirimidindiamina za zdravljenje ali preventivo avtoimunih bolezni
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009004061A (es) Compuestos organicos.
EP1991218A4 (fr) Utilisation de cyclolignans dans le traitement du diabète de type 2 et comme contraceptifs
WO2008027687A3 (fr) Méthode de traitement d'avc à l'aide d'un agent thrombolytique
HK1084037A1 (en) Medicament for treating severe heart failure
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
SI2380584T1 (sl) Imunostimulatorni postopek
WO2008011478A3 (fr) Procédés de traitement de douleur chronique utilisant des amides d'acide 3-aryl-3-hydroxy-2-amino-propioniques, amides d'acide 3-hétéroaryl-3-hydroxy-2-amino-propionique et composés connexes
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
WO2006138372A3 (fr) Procedes et reactifs pour le traitement de troubles inflammatoires
WO2008016640A3 (fr) Traitement de l'insuffisance cardiaque progressive chronique
WO2006089286A3 (fr) Composes utiles pour traiter et prevenir la douleur et procedes de criblage associes
WO2006121995A3 (fr) Methodes de traitement de la nephrolithiase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06849092

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06849092

Country of ref document: EP

Kind code of ref document: A2